LABT Lakewood-Amedex Biotherapeutics Inc.

CIK 0002079272 2 ready 8-Ks latest June 17, 2026, 11:40 AM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 0 baseline

Ready 8-Ks 2

Latest filing June 17, 2026, 11:40 AM ET

Top materiality 0.65

Event mix other_material ×1 · leadership ×1

Sentiment 1 pos · 0 neg · 1 neu

Executive change recent →

SHENANIGAN SCORE 1 / 7 see the board

Recent 8-K filings for LABT

Highest-materiality recent filing

Lakewood-Amedex announces 1-for-10 reverse stock split effective June 19, 2026

June 17, 2026, 11:40 AM ET other material materiality 0.65 neutral item 3.03 item 5.03 item 9.01 ◈ Governance Changes

Reverse split ratio: 1-for-10; effective at 4:01 p.m. ET on June 19, 2026; trading starts split-adjusted on Nasdaq June 22.
Outstanding shares reduced from ~17,506,577 to ~1,750,789; fractional shares rounded up to next whole share.

Read filing →

June 17, 2026, 11:40 AM ET other material materiality 0.65 neutral item 3.03 item 5.03 item 9.01 ◈ Governance Changes

Lakewood-Amedex announces 1-for-10 reverse stock split effective June 19, 2026

Reverse split ratio: 1-for-10; effective at 4:01 p.m. ET on June 19, 2026; trading starts split-adjusted on Nasdaq June 22.

Executive changes

Appointed

Joseph Tucker

Director

LABT · Lakewood-Amedex Biotherapeutics Inc.

Effective: 2026-04-24
Filed: April 28, 2026, 7:59 PM ET

On April 24, 2026, the Board of Directors (the “Board”) of Lakewood-Amedex Biotherapeutics Inc. (the “Company”) appointed Dr. Joseph Tucker to fill a vacancy and serve as a member of the Board, effective April 24, 2026.

Materiality & sentiment trend

Max materiality 0.65 · Median 0.57 · Most common event other_material

1 positive 0 negative 1 neutral

source · LABT on sec.gov